<DOC>
	<DOCNO>NCT00538785</DOCNO>
	<brief_summary>The primary goal describe safety investigational product give monthly prevent serious respiratory infection among child significant heart disease .</brief_summary>
	<brief_title>A Study Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease</brief_title>
	<detailed_description>The primary objective describe safety tolerability motavizumab give monthly prophylaxis serious RSV infection among child hemodynamically significant congenital heart disease .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>24 month age young randomization ( child must randomize 24month birthday ) Documented , hemodynamically significant CHD Unoperated partially correct CHD Written inform consent obtain patient 's parent ( ) /legal guardian ( ) Note : The following child eligible : child uncomplicated small atrial ventricular septal defect patent ductus arteriosus , child aortic stenosis , pulmonic stenosis , coarctation aorta alone . Children acyanotic cardiac lesion must pulmonary hypertension [ ≥ 40 mmHg measure pressure pulmonary artery ( PA ) ] need daily medication manage CHD . Unstable cardiac respiratory status , include cardiac defect severe survival expect cardiac transplantation plan anticipated Hospitalization , unless discharge anticipate within 21 day Anticipated cardiac surgery within two week randomization Requirement mechanical ventilation , extracorporeal membrane oxygenation , continuous positive airway pressure mechanical respiratory cardiac support Associated noncardiac anomaly end organ dysfunction result anticipated survival less six month unstable abnormality end organ function Acute respiratory illness , acute infection illness Note : child respiratory symptom must negative RSV test prior randomization Chronic seizure evolve unstable neurologic disorder Known immunodeficiency Mother HIV infection ( unless child proven infect ) Known allergy Ig product Receipt polyclonal antibody ( example , Hepatitis B IG , IVIG , VZIG ) within 3 month prior randomization Receipt palivizumab ( Synagis® ) within 3 month prior randomization Use investigational agent within past three month ( investigational agent commonly use cardiac surgery immediate postoperative period , e.g. , nitric oxide ) Current participation investigational protocol drug biological agent Previous participation MICP124 ( Season 1 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Synagis , motavizumab , palivizumab , child , MEDI-524 , RSV , congenital hear disease</keyword>
</DOC>